Dr. Richard Harris on Advancements on the Horizon in Prostate Cancer
November 4th 2016Richard Harris, MD, of UroPartners, says there are many exciting advancements currently happening in the field of prostate cancer. Harris shared his insights during an interview with OncLive at the 2016 LUGPA Annual Meeting.
Dr. Gary Kirsh on This Exciting Phase in Prostate Cancer Care
November 4th 2016Gary Kirsh, MD, President of The Urology Group and the Large Urology Group Practice Association (LUGPA), discusses this exciting phase in prostate cancer care. Kirsh shared his insights during an interview with OncLive at the 2016 LUGPA Annual Meeting.
Physician Dispensing of Abiraterone and Enzalutamide for mCRPC Gains Appeal
November 7th 2015With the emergence of the novel treatments abiraterone acetate (Zytiga) and enzalutamide (Xtandi), urology groups are beginning to offer in-office dispensing to their metastatic castration-resistant prostate cancer patients.
Recently Approved Therapies Bring New Understanding in Management of Prostate Cancer
After many years of treating patients with advanced prostate cancer the same way, a host of new drug approvals has not only changed the way urologists manage prostate cancer but their understanding of the disease as well.